Biomanufacturing holds exceptional promise to replace unsustainable manufacturing methods in a plethora of industries, yet so far very few biomanufacturing processes have proven economic feasibility outside of low volume, high margin markets. Fermeate’s photomolecular switch technology, developed over the past 11 years in the Avalos lab at Princeton University, provides the missing dynamic control needed to unlock unprecedented efficiency in biomanufacturing. Their technology is a drop into existing fermentation infrastructure: no new steel tanks required, and they already have 4 industrial partners in the food, fuel, agriculture, and specialty chemicals sectors.

There are over 1000 thermal power plants that use seawater to cool their reactors, but pumping in seawater inevitably leads to clogged pipes that eat up power generation efficiency, a huge nightmare for the power plant to deal with. Ceal has a patented electrolysis system that optimizes the mineralization efficiency. They “soften” the water for the power plant to eliminate the clogging, while also sequestering CO2; every 1 ton of CO2 removed can generate $200M revenue in precipitated calcium carbonate, and $6M in opex savings for the power plant. The additional CDR revenue is just the cherry on top.

Sixty years ago, researchers discovered that plants have an “acquired immune system” just like humans do, but nobody knew how to fully activate it without decreasing crop yields. Phytogenesis founders have discovered how to do exactly that. Their PrevSAR, their RNA-based activator has been tested in 26 field trials that show broad spectrum pathogen defense, as well as targeted pathogen defense. Interestingly, this heightened state of defense continues after crops have been harvested, which prolongs shelf-life as it makes its way to the grocery store. No other company has been able to deliver a triple threat in one product, for under $1 an acre in COGS.

Over 2 million Americans suffer from Type I Diabetes (T1D) and have to take over 10,000 insulin injections in a 5 year period just to manage their condition. Minutia is pioneering a functional cure for T1D which can replace all these injections with one simple implant in the forearm. Further, it does not require systemic immunosuppressants and has built in non-genetic, nanoparticle-based safety features, making it applicable for the full T1D population and even the insulin-dependent Type 2 diabetics.

To book time with the founder, please email:Samie@minutia.co,katy@minutia.co

Biofouling drains billions of dollars annually across industries by clogging pipelines, contaminating medical devices, degrading marine equipment, fouling ship hulls, and compromising water treatment systems. Disperse Bio has discovered the most potent anti-biofouling agent, which is predicated on dispersing instead of killing the bacteria. With a 99% margin on the active ingredient, they can save billions of dollars for industries while also making hundreds of millions for themselves.

Within minutes of being in the sunlight, our skin DNA starts to “crack” at two very specific types of bonds, and the failure to repair those cracks is the cause of all skin-related aging. Antarka is a B2B beauty ingredients company powered by novel enzymes discovered in the ice of Antarctica. Their hero product is the fastest enzyme discovered to completely repair the DNA damage in your skin. This is being formulated into nine different beauty products (and counting), from protective formulations to a nighttime repair serum. Their enzyme is the only one on the market with the scientific transparency to show both cell penetration and efficacy.

The biology-powered future of everything depends on one thing: printing DNA. And the “AI x Bio” future requires large amounts of training data derived from high-throughput experiments, the enablement of which is: printing many thousands of variants of DNA. Synplexity makes lots of custom-sequence DNA, cheaper, longer, and more numerous than anybody else. This way, ““Synplexity is solving a key bottleneck in the “Make” part of the Design-Make-Test-Analyze cycle that fuels modern bio. Synplexity is already shipping DNA to paying customers, hitting first revenue just 4 months after we funded them.

Dr. Shebani Sethi has been dubbed “The Mother of Metabolic Psychiatry,” a new practice of treating severe mental illness using her insights into the “drug-diet-ketosis interaction” effects in the brain. Her protocols and systems have been clinically validated to show an 80% success rate in bipolar and schizophrenic patients, and she is now scaling her practice into a digital health solution for patients and providers, enabling anyone to access her proprietary add-on treatment management platform.